OncRef

Clinical Trial: NCT03677154

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Hoffmann-La Roche
Information Provided By:Hoffmann-La Roche
Last Update Posted:2025-08-21

Study Overview

Brief Summary

This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy in participants with a best response of stable disease or partial response, or in elderly/unfit participants with previously untreated DLBCL, or subcutaneous mosunetuzumab in combination with polatuzumab vedotin IV in elderly/unfit participants with previously untreated DLBCL.

Official Title

A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Conditions

Diffuse Large B-cell Lymphoma

Intervention / Treatment

  • Drug: Mosunetuzumab Intravenous (IV)
  • Drug: Mosunetuzumab Subcutaneous (SC)
  • Drug: Polatuzumab Vedotin
  • Drug: Tocilizumab

Other Study ID Numbers

  • GO40554

Start Date (Actual)

2019-05-23

Primary Completion Date (Actual)

2025-08-07

Study Completion Date (Actual)

2025-08-07

Enrollment (Actual)

188

Study Type

Interventional

Phase

Phase 1, Phase 2